Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Attention Deficit Hyperactivity Disorder: full-pipeline trial registry
29 of 103 indexed Attention Deficit Hyperactivity Disorder trials are currently recruiting.
Corpus placement: #130 of 28,707 conditions by registered trial count.
103 US clinical trials · 29 currently recruiting · #130 of 28,707 conditions by registered trial count
Attention Deficit Hyperactivity Disorder: 103 US clinical trials tracked, 29 recruiting.
Attention Deficit Hyperactivity Disorder is the subject of 103 registered US clinical trials on ClinicalTrials.gov, 29 of them currently open to new participants. 27 are in Phase 3-4 (later-stage) and 24 in Phase 1-2 (earlier-stage). The most active sponsor is Massachusetts General Hospital, running 9 of these trials.
Enrollment posture brief
Registry condition attention-deficit-hyperactivity-disorder
OPEN 29 | RECR 28% | LATE 27 | EARLY 24 | RANK #130 | SPON 9
Volume-matched condition peers
Nearest open-share peer: Astigmatism (28% recruiting · 32 trials)
Attention Deficit Hyperactivity Disorder lists 29 open slots (28% of 103 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Attention Deficit Hyperactivity Disorder on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Attention Deficit Hyperactivity Disorder is recruiting below its size-band peers.
29 of 103 indexed trials (28.2%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Attention Deficit Hyperactivity Disorder trials is spread across many organizations.
Massachusetts General Hospital accounts for 9 of 103 trials (8.7%). 64 distinct sponsors appear on at least one study for this condition label.
-
Typical Attention Deficit Hyperactivity Disorder enrolment sits around 71 participants.
Median target enrolment is 71 among the 103 trials that report a genuine target (sentinel values excluded). 56 of those (54.4%) plan for fewer than 100 participants.
-
Attention Deficit Hyperactivity Disorder research is mostly interventional.
97 interventional and 6 observational studies make up this index (94.2% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
103 total, page 1 of 3
Developing Brain, Impulsivity and Compulsivity
National Institute of Mental Health (NIMH)
NCT04631042
Transcranial Direct Current Stimulation (tDCS) Neuromodulation of Executive Function Across Neuropsychiatric Populations
Massachusetts General Hospital
NCT04296604
Neurocognitive Effects of Non-Invasive Near-Infrared Light Stimulation
University of Texas at Austin
NCT05802680
Carboxylesterase 1 Genetic Variation and Methylphenidate in ADHD
Icahn School of Medicine at Mount Sinai
NCT03781752
BUILT Family Lifestyle Program for Children with ADHD
University of Illinois at Chicago
NCT05464056
Interventions for English Language Learners At-Risk for ADHD
Florida International University
NCT05918991
Evaluation of SPN-812 (Viloxazine Extended-release Capsule) in Preschool-age Children With ADHD
Supernus Pharmaceuticals
NCT04781140
Efficacy of Trigeminal Nerve Stimulation for ADHD
University of California, Los Angeles
NCT05374187
R61/33 - VR Study Phase 4
Rutgers, The State University of New Jersey
NCT07169760
HOPS Study: A Conceptual Replication
Children's Hospital of Philadelphia
NCT04465708
Development of Virtual Reality-based Interventions to Strengthen Cognitive Skillsets Related to Attention Deficit Hyperactivity Disorder (ADHD): A Pilot Phase I and Randomized Controlled Phase II Trial
National Institute of Mental Health (NIMH)
NCT05608434
Project PEAK: Early Intervention for ADHD
Lehigh University
NCT04627415
Motor Attention Training for Attention Deficit Hyperactivity Disorder (ADHD)
University of Wisconsin, Madison
NCT02688959
Enhancing Team Effectiveness for a Collaborative School-based Intervention for ADHD
University of California, San Diego
NCT06180681
Mindfulness Intervention for College Students With ADHD
University of Alabama, Tuscaloo
NCT06076967
The Effects of Cannabigerol on Attention-Deficit/Hyperactivity Disorder
University of Arkansas, Fayetteville
NCT06115603
COMT Inhibition Among Individuals With Comorbid AUD/ADHD
University of Colorado, Denver
NCT03904498
A Trial of Dyanavel XR in Treating Co-occurring Fatigue Symptoms in Adults With Attention Deficit Hyperactivity Disorder (ADHD).
Rochester Center for Behavioral Medicine
NCT06248229
Optimizing Attention and Sleep Intervention Study
University of Pittsburgh
NCT05683756
Acute Effects of Exercise in College Students With ADHD
University of Wyoming
NCT03666416
Stimulant vs. Non-stimulant Treatments and Reward Processing in Drug-naive Youth at SUD Risk
Icahn School of Medicine at Mount Sinai
NCT03781765
ADHD PreSMA Response Inhibition Therapy
Children's Hospital Medical Center, Cincinnati
NCT06325813
Acute Effects of Stimulant Medication in College Students With ADHD
University of Wyoming
NCT03935646
A Pilot Study of a Remote ADHD Monitoring Program
IDeA States Pediatric Clinical Trials Network
NCT06743425
Trigeminal Nerve Stimulation for Children With Prenatal Alcohol Exposure
University of California, Los Angeles
NCT06847165
Focus Groups in Ethnically and Racially Diverse Families
Oregon Health and Science University
NCT05930886
Optimizing Research With Diverse Families - Feasibility and Acceptability Study (FAST)
Oregon Health and Science University
NCT06133231
An Open-Label Treatment With Randomization Observation, Investigator-Initiated Study, on the Duration and Efficacy of Jornay PM (Methylphenidate Hydrochloride Extended-Release Capsules) on Adult ADHD Symptoms and Executive Function and Emotional Regulation Throughout the Day Into Early Evening
NYU Langone Health
NCT06577779
Stimulant Effects on Disruptive Behavior
Matthew J O'Brien, PhD, BCBA-D
NCT03420339
Brain Imaging of Childhood Onset Psychiatric Disorders, Endocrine Disorders and Healthy Volunteers
National Institute of Mental Health (NIMH)
NCT00001246
Open-label Study to Evaluate Long-term Safety and Efficacy of SPN-812 (Viloxazine Extended-release Capsule)
Supernus Pharmaceuticals
NCT02736656
A Trial of Centanafadine Long-term Safety in Children and Adolescents With Attention-deficit/Hyperactivity Disorder.
Otsuka Pharmaceutical Development & Commercialization
NCT05279313
Outcomes of Cognitive Behavioral Therapy (CBT) Interventions Provided by Unlicensed Professionals
Massachusetts General Hospital
NCT01075672
Family Navigation to Improve ADHD Treatment Adherence for Minority Children
Children's Hospital Medical Center, Cincinnati
NCT04591951
A Dose-Response Study of the Cognitive and Physiological Effects of tDCS to the DLPFC
Massachusetts General Hospital
NCT04175041
Personalized Attention-Deficit/Hyperactivity Disorder (ADHD) Medication Experiment Study
Children's Hospital Medical Center, Cincinnati
NCT06305078
Settling Down for Sleep in ADHD: The Impact of Sensory and Arousal Systems on Sleep in ADHD
University of Pittsburgh
NCT06406309
Educating and Supporting Primary Care Providers in the Implementation of Evidence-based Practices for ADHD
Children's Hospital of Philadelphia
NCT02271386
Study of the Safety and Efficacy of OPC-34712 as a Complementary Therapy in the Treatment of Adult Attention Deficit/Hyperactivity Disorder
Otsuka Pharmaceutical Development & Commercialization
NCT01074294
Efficacy and Safety Study of Methylphenidate Hydrochloride Extended Release in Adults With Childhood-onset Attention Deficit/Hyperactivity Disorder (ADHD)
Novartis Pharmaceuticals
NCT01259492
Treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) With Atomoxetine in Young Adults and Its Effects on Functional Outcomes
Eli Lilly and Company
NCT00510276
Study to Assess the Safety and Efficacy of NRP104 in Adults With Attention-Deficit Hyperactivity Disorder (ADHD)
New River Pharmaceuticals
NCT00334880
Dose-Finding Study to Evaluate the Efficacy and Safety of Modafinil as Treatment for Adults With ADHD
Cephalon
NCT00315276
A Study of Pediatric Patients With Attention Deficit/Hyperactivity Disorder
Eli Lilly and Company
NCT00922636
Adult Attention Deficit Hyperactivity Disorder (ADHD) Study With Amphetamine Sulfate
Arbor Pharmaceuticals
NCT03659929
Adolescent Changes in Brain and Behavior in Boys and Girls With ADHD
Hugo W. Moser Research Institute at Kennedy Krieger
NCT05927506
Long Term Safety Study of Study Drug (Eszopiclone) in Children and Adolescents With ADHD -Associated Insomnia
Sumitomo Pharma America
NCT00857220
A Study of TD-9855 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)
Theravance Biopharma
NCT01458340
STAND Community Trial
Florida International University
NCT02694939
Neurophysiological Attention Test (NAT) for Objective Assessment of Adult ADHD
Think Now Incorporated
NCT02756286
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 8 |
| Phase 2 | 16 |
| Phase 3 | 10 |
| Phase 4 | 17 |
Top Sponsors
Named interventions
Most-linked intervention names on Attention Deficit Hyperactivity Disorder records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Attention Deficit Hyperactivity Disorder trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Attention Deficit Hyperactivity Disorder page
103 registered trials, 29 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 29 Attention Deficit Hyperactivity Disorder trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Massachusetts General Hospital sponsors the most Attention Deficit Hyperactivity Disorder trials on record, review their full trial history before evaluating a specific study. See Massachusetts General Hospital's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Attention Deficit Hyperactivity Disorder condition card totals 103 registered trials; most-linked intervention Placebo; top US site state New York. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.